Ovarian cancer, the coagulation pathway, and inflammation

Por Kavanagh John J, Wang Ena, Wang Xipeng, Freedman Ralph S
Publicado em 2005-06-01

Ovarian cancer, the coagulation pathway, and inflammation

Por Wang, Xipeng, Wang, Ena, Kavanagh, John J, Freedman, Ralph S
Publicado em 2005

Sustained Complete Response after Maintenance Therapy with Topotecan and Erlotinib for Recurrent Cervical Cancer with Distant Metastases

Por Callegaro-Filho, Donato, Kavanagh, John J., Nick, Alpa M., Ramirez, Pedro T., Schmeler, Kathleen M.
Publicado em 2014

Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion

Por Lee, Eun-Ju, Mircean, Cristian, Shmulevich, Ilya, Wang, Huamin, Liu, Jinsong, Niemistö, Antti, Kavanagh, John J, Lee, Je-Ho, Zhang, Wei
Publicado em 2005

Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum

Por Gershenson, David M., Sun, Charlotte C., Iyer, Revathy B., Malpica, Anais L., Kavanagh, John J., Bodurka, Diane C., Schmeler, Kathleen, Deavers, Michael
Publicado no Gynecol Oncol (2012)

Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells

Por Li, Yanfang, Liu, Tao, Ivan, Cristina, Huang, Jie, Shen, De-Yu, Kavanagh, John J., Bast, Robert C., Fu, Siqing, Hu, Wei, Sood, Anil K.
Publicado em 2013

Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer

Por Kavanagh, John J, Levenback, Charles F, Ramirez, Pedro T, Wolf, Judith L, Moore, Carla L, Jones, Marsha R, Meng, Lisa, Brown, Gail L, Bast, Robert C
Publicado em 2010

Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3

Por Fu, Siqing, Li, Yanfang, Huang, Jie, Liu, Tao, Hong, Zhen, Chen, Aiping, Bast, Robert C, Kavanagh, John J., Gershenson, David M, Sood, Anil K, Hu, Wei
Publicado em 2012

Phase Ib-IIa study to reverse platinum resistance by the use of a hypomethylating agent azacitidine in platinum-resistant or refractory epithelial ovarian cancer

Por Fu, Siqing, Hu, Wei, Iyer, Revathy, Kavanagh, John J., Coleman, Robert L., Levenback, Charles F., Sood, Anil K., Wolf, Judith K., Gershenson, David M., Markman, Maurie, Hennessy, Bryan T., Kurzrock, Razelle, Bast, Robert C.
Publicado em 2010

Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer

Por Fu, Siqing, Hennessy, Bryan T., Ng, Chaan S., Ju, Zhenlin, Coombes, Kevin R., Wolf, Judith K., Sood, Anil K., Levenback, Charles F., Coleman, Robert L., Kavanagh, John J., Gershenson, David M., Markman, Maurie, Dice, Kristine, Howard, Adrienne, Li, Jane, Li, Yang, Stemke-Hale, Katherine, Dyer, Mary, Atkinson, Edward, Jackson, Ed, Kundra, Vikas, Kurzrock, Razelle, Bast, Robert C., Mills, Gordon B.
Publicado em 2012